The global interventional oncology market size was estimated at USD 2.7 billion in 2024 and is projected to reach USD 4.38 billion by 2030, growing at a CAGR of 8.55% from 2025 to 2030. Several key factors are driving this market growth, including the rising global incidence of cancer, continuous advancements in minimally invasive technologies, an aging global population, a growing emphasis on early cancer diagnosis, and increased investments—both public and private—targeted at developing interventional oncology solutions.

The incidence of cancer worldwide is on a steep upward trajectory, resulting in heightened demand for innovative and effective cancer treatment approaches. Data from the World Health Organization (WHO) indicates that in 2022, there were approximately 20 million new cancer cases, accompanied by 9.7 million related deaths. Projections suggest that by 2050, the number of new cancer cases will exceed 35 million annually, representing a 77% increase in the global cancer burden compared to current levels.

Interventional oncology is increasingly recognized for its ability to provide effective cancer treatment through a range of minimally invasive procedures, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cryoablation. These techniques offer several advantages over conventional surgical methods, including shorter hospital stays, quicker recovery periods, and a reduced risk of complications. As the global burden of cancer continues to escalate, the demand for these advanced interventional treatments is expected to grow rapidly. Their proven ability to enhance patient outcomes and overall quality of life further supports their rising adoption in clinical practice worldwide.

Key Market Trends & Insights:

• In 2024, North America emerged as the leading region in the global interventional oncology market, holding a dominant revenue share of 41.87%. This strong regional performance can be attributed to the presence of advanced healthcare infrastructure, widespread adoption of innovative medical technologies, and a high prevalence of cancer cases across the continent.

• Within North America, the United States is expected to experience substantial growth in the interventional oncology market over the forecast period. This anticipated growth is driven by increasing investments in healthcare, ongoing technological advancements, and a growing demand for minimally invasive cancer treatment options.

• Analyzing the market by technique, ablation therapies led the segment and accounted for the largest revenue share of 37.1% in 2024. This leadership position reflects the growing preference for ablation methods due to their effectiveness, safety profile, and ability to target tumors with minimal impact on surrounding healthy tissues.

• Based on procedural classification, the vascular interventions segment secured the highest revenue contribution, representing 38.2% of the total market in 2024. This dominance highlights the importance of vascular procedures in interventional oncology, particularly for delivering targeted therapies through the blood vessels to treat various types of cancer.

• From an application standpoint, liver cancer represented the largest share of the interventional oncology market, contributing 28.0% to the total revenue in 2024. This significant share is primarily due to the high incidence of liver cancer globally and the proven efficacy of interventional procedures, such as transarterial chemoembolization and ablation, in managing this type of cancer.

Order a free sample PDF of the Interventional Oncology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 2.7 Billion

• 2030 Projected Market Size: USD 4.38 Billion

• CAGR (2025-2030): 8.55%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Leading companies operating in the interventional oncology market are actively implementing a range of strategic initiatives aimed at reinforcing their market position and expanding the availability and accessibility of their products and services across different regions. These efforts are crucial in driving the overall growth and competitiveness of the market.

Among the key strategies being adopted, expansion activities—such as the establishment of new production facilities, entry into emerging markets, and the enhancement of distribution networks—are enabling these players to cater to a broader patient base and meet the rising demand for interventional oncology solutions.

In addition, partnerships and collaborations with hospitals, research institutions, and other healthcare stakeholders are becoming increasingly common. These alliances are facilitating technological innovation, accelerating product development, and enhancing clinical outcomes, all of which contribute to improved market performance and long-term growth potential.

Key Players

• Medtronic plc

• Boston Scientific Corporation

• Johnson & Johnson (Ethicon)

• Teleflex Incorporated

• Cook Medical

• AngioDynamics Inc.

• Stryker Corporation

• Profound Medical

• Terumo Corporation

• Siemens Healthineers

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The interventional oncology market is experiencing rapid expansion, propelled by the rising global cancer burden and increasing demand for minimally invasive treatment options. Technological innovations—such as enhanced image-guided ablation and vascular intervention techniques—are enabling more precise and effective tumor targeting with faster recovery times. Key market players are actively driving growth through global expansion, strategic partnerships, and development of new product offerings. Additionally, robust support from regulatory agencies and growing investments from both public and private entities are further accelerating the adoption of interventional oncology solutions. Overall, the market is poised for sustained momentum as advanced therapeutic alternatives continue to gain traction within cancer care.